Explore

Trendline Trendline
Brainstorm Cell Therapeutics Reports Narrower Loss in Q1 2026 Amid Clinical Developments

Brainstorm Cell Therapeutics Reports Narrower Loss in Q1 2026 Amid Clinical Developments

Brainstorm Cell Therapeutics Reports Narrower Loss in Q1 2026 Amid Clinical Developments
Trendline Trendline
Alpha Cognition Reports Strong Q1 2026 Financial Results Amid ZUNVEYL's Growing Market Adoption

Alpha Cognition Reports Strong Q1 2026 Financial Results Amid ZUNVEYL's Growing Market Adoption

Alpha Cognition Reports Strong Q1 2026 Financial Results Amid ZUNVEYL's Growing Market Adoption
Trendline Trendline
Alpha Cognition Reports Q1 2026 Financial Results Highlighting Revenue Growth and Clinical Advancements

Alpha Cognition Reports Q1 2026 Financial Results Highlighting Revenue Growth and Clinical Advancements

Alpha Cognition Reports Q1 2026 Financial Results Highlighting Revenue Growth and Clinical Advancements
Trendline Trendline
Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue

Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue

Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue
Trendline Trendline
Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026

Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026

Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026
Trendline Trendline
Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates

Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates

Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates
Trendline Trendline
Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase
Trendline Trendline
Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress

Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress

Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress
Trendline Trendline
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026

Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026

Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026
Trendline Trendline
Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion

Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion

Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion
Trendline Trendline
CervoMed Faces Financial Challenges Amid Clinical Advancements

CervoMed Faces Financial Challenges Amid Clinical Advancements

CervoMed Faces Financial Challenges Amid Clinical Advancements
Trendline Trendline
CervoMed Reports $7.96M Net Loss in Q1 2026 Amid Clinical Investments

CervoMed Reports $7.96M Net Loss in Q1 2026 Amid Clinical Investments

CervoMed Reports $7.96M Net Loss in Q1 2026 Amid Clinical Investments